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ABSTRAK
Tujuan: mengetahui prevalensi resistensi laboratorik ASA dengan uji fungsi trombosit pada pasien stroke 
iskemik di RSCM dan faktor-faktor yang berhubungan. Metode: desain penelitian potong lintang melibatkan 
50 penderita stroke iskemik yang hanya mendapatkan terapi ASA. Pemeriksaan resistensi ASA dengan uji 
fungsi trombosit Verifynow®. Resistensi ASA dinyatakan jika ASA reaction unit (ARU) ≥550. Hasil: didapatkan 
7 penderita resistensi ASA. Kelompok resistensi ASA memiliki rerata usia 51,3±9,2 tahun sementara kelompok 
respons ASA memiliki rerata usia 57,8±9,7 tahun. Pada kelompok resistens ASA 85,7% berjenis kelamin laki-laki, 
57,1% perokok aktif dan 100% menderita hipertensi. Kesimpulan: didapatkan prevalensi resistensi laboratorik 
ASA dengan uji fungsi trombosit pada penderita stroke iskemik di RSCM sebesar 14%. Terdapat kecenderungan 
prevalensi resistensi laboratorik ASA lebih banyak terjadi pada penderita laki-laki, perokok aktif, berusia lebih 
muda dan menderita hipertensi.
Kata kunci: stroke iskemik, resistensi ASA, uji fungsi trombosit.
ABSTRACT
Aim: to identify the prevalence of laboratoric ASA resistance using platelet function tests in patients 
with ischemic stroke at Cipto Mangunkusumo Hospital and its associated factors. Methods: this study was a 
cross-sectional study involving 50 patients with ischemic stroke who only received ASA treatment. Evaluation 
of resistance to ASA was performed using Verifynow® platelet function test. ASA resistance was defined as 
ASA reaction unit (ARU) ≥550. Results: there were 7 patients with ASA resistance. The mean age of subjects 
in ASA resistance group was 51.3±9.2 years; while in ASA responsive group was 57.8±9.7 years. In ASA 
resistance group, there were 85.7% male patients, 57.1% active smoker and 100% subjects with hypertension. 
Conclusion: the prevalence of laboratoric ASA resistance in patients with ischemic stroke evaluated using 
platelet function test at Cipto Mangunkusumo Hospital is 14%. The prevalence is more likely to occur in male 
patients who were active smoker, at younger age and with comorbidity of hypertension.
Key words: ischemic stroke, ASA resistance, platelet function test.
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INTRODUCTION 
Stroke patients are at high risk of recurrent 
ischemic stroke, which leads to high mortality 
and morbidity rates.1,2 A study in Indonesia shows 
20% incidence of recurrent stroke, particularly 
ischemic stroke.3
Antiplatelet agents are drugs that inhibit 
platelet aggregation and prevent thrombus 
formation, thus prevent recurrent ischemic 
stroke. Acetyl salicylic acid (ASA) is an effective 
antiplatelet agent widely used for secondary 
prevention of recurrent ischemic stroke.4,5
Some studies found a group of patients that 
do not experience beneficial effects of ASA 
treatment. Many factors have been assumed to 
be the causes including non-optimal ASA dose, 
non-compliance and genetic polymorphism, 
which may lead to ineffective ASA treatment. 
Patients who do not respond to ASA treatment 
are called as ASA resistance.5,6 Some studies have 
demonstrated that patients with ASA resistance 
are associated with poorer prognosis compared 
to those who respond well to ASA treatment.5,7,8
Until now, there is no data about the 
prevalence of ASA resistance in patients with 
ischemic stroke in Indonesia, especially at Cipto 
Mangunkusumo Hospital. Therefore, this study 
was aimed to demonstrate laboratoric ASA 
resistance using platelet function test in patients 
with ischemic stroke at Cipto Mangunkusumo 
Hospital and its associated factors.
METHODS
This is a cross-sectional study on patients 
with ischemic stroke conducted in the ward and 
outpatient unit of Cipto Mangunkusumo Hospital 
between April and May 2014. Subjects were 
recruited by consecutive sampling. The inclusion 
criteria were adult patients diagnosed as ischemic 
stroke with or without imaging features, those 
who had ischemic stroke for the first time and 
received 80 mg ASA treatment for at least 5 days. 
The exclusion criteria were patients who used 
antiplatelet/anticoagulants other than ASA and 
non-compliance to the treatment.
ASA resistance or response was evaluated 
based on Verifynow® platelet function test. The 
Verifynow® platelet function test is a simple, fast 
and accurate method which has been validated 
with the gold standard of platelet function test 
using light transmittance aggregometry (LTA).7 
The threshold level of ASA reaction unit (ARU) 
was used to define one’s non-responsiveness 
(resistance ) to ASA. ASA resistance was defined 
as ARU≥550.9-11
RESULTS
There were 50 patients with ischemic stroke 
for the first time, who were using only ASA as 
their single antiplatelet treatment and they were 
taking 80 mg ASA regularly for at least 5 days. 
The mean age of all subjects was 56.8±9.8 
years. Twenty nine (58%) subjects were male 
patients. Most patients with stroke were at the 
age group of 40-65 years, i.e. at 39 years (78%). 
Of all subjects, sixteen subjects (32%) were 
categorized as patients with new ischemic stroke 
who were having or had hospitalization at the 
ward with range of stroke onset of 6 - 24 days; the 
remaining 34 (68%) subjects were patients with 
old ischemic stroke who were having routine 
visit to outpatient unit with range of stroke onset 
of 1.5 months to 9 years.
The highest percentage of concomitant 
disease was hypertension, i.e. 49 (98%) subjects, 
followed by dyslipidemia in 23 (46%) subjects, 
diabetes in 15 (30%) subjects, inflammation in 
5 (10%) subjects; while CAD and infection had 
the lowest percentage, i.e. 4 (8%) subjects.
The majority of subjects received ASA 
in the form of non-enteric coating, i.e. 27 
(54%) subjects. The most common side effect 
complained by the users was gastric pain. Twenty 
three (46%) subjects had short-duration ASA 
treatment with the range of 5-24 days. Ten (30%) 
subjects who were the new user of ASA treatment 
had a loading dose of 320 mg at the beginning of 
treatment, i.e those with acute ischemic stroke 
with onset of <48 hours.
Seven (14%) subjects with ASA treatment, 
also had PPI treatment, but there was no 
subject  receiving NSAID as anti-inflammatory 
treatment. Data of subject characteristics on 
sociodemography, concomitant disease and ASA 
treatment for all subjects can be seen in Table 1.
The majority of stroke ischemic patients 
with hypertension had controlled systolic and 
diastolic blood pressure, either with single 
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or combined anti-hypertensive agent(s). The 
majority of stroke ischemic patients with diabetes 
also had controlled glucose level, either with 
hypoglycemic agent alone or combined treatment 
with insulin. Data of clinical and laboratory 
characteristics of all subjects can be seen in 
Table 2.
The prevalence of laboratory ASA resistance 
in patients with ischemic stroke at Cipto 
Mangunkusumo Hospital in our study was 14%. 
The group responsive to ASA treatment had ARU 
score with median value of 421 (350-548); while 
the ASA resistance group had ARU score with 
median of 650 (556-666).
Higher prevalence of ASA resistance was 
also found in male patients compared to female 
patients, aged 40-65 years, with old ischemic 
stroke and active smoker compared to those with 
no / had stopped smoking (Table 3). However, 
further statistic tests were not performed due to 
a small sample size.
The description on the prevalence of ASA 
resistance with concomitant disease revealed that 
all patients with ASA resistance had hypertension, 
3 patients (42.85%) had dyslipidemia and only 
1 patient had diabetes or CAD or inflammation. 
The description on the prevalence of ASA 
resistance and the characteristics of concomitant 
disease can be seen in Table 4.
The description on prevalence of ASA 
resistance with clinical and laboratory 
characteristics demonstrated younger age 
of subjects in ASA resistance group. For 
other parameters, there was no difference 
between subjects in ASA resistance group and 
ASA responsive group. The description of 
ASA resistance with clinical and laboratory 
characteristics can be seen in Table 5.
The description on prevalence of ASA 
resistance with characteristics of ASA treatment 
(Table 6) revealed that there were 71.4% subjects 
in ASA resistance group received ASA treatment 
without enteric coating, 1 patient had received 
loading dose at the beginning of the treatment 
and subjects in ASA resistance group did not 
have drug interaction with NSAID or PPI.
Table 1. Characteristics of sociodemography, concomitant 
disease and ASA treatment of all subjects
Characteristics N (%)
Sex
 - Male 29 (58%)
 - Female 21 (42%)
Age group
 - < 40 years 3 (6%)
 - 40 – 65 years 39 (78%)
 - > 65 years 8 (16%)
Stroke Onset 
 - New stroke 16 (32%)
 - Old stroke 34 (68%)
Smoking
 - Active 9 (18%)
 - No / stop smoking 41 (82%)
Hypertension
 - Yes 49 (98%)
 - No 1 (2%)
Diabetes
 - Yes 15 (30%)
 - No 35 (70%)
Dyslipidemia
 - Yes 23 (46%)
 - No 27 (54%)
CAD 
 - Yes 4 (8%)
 - No 46 (92%)
Infection
 - Yes 4 (8%)
 - No 46 (92%)
Inflammation
 - Yes 5 (10%)
 - No 45 (90%)
Duration of ASA treatment
 - Short duration 23 (46%)
 - Long duration 27 (54%)
ASA loading dose
 - Given 40 (80%)
 - Not given 10 (20%)
Interaction with NSAID
 - Present 0 (0%)
 - Absent 50 (100%)
Interaction with PPI
 - Present 7 (14%)
 - Absent 43 (86%)
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DISCUSSION
Subject characteristics in our study 
demonstrated that there were larger number of 
male subjects with ischemic stroke than female, 
i.e. 58% vs 42% (1.3 : 1). Based on the age group, 
the largest number of stroke patients was at the 
age of 40-65 years (78%). Regarding the risk 
factors, hypertension had the highest percentage 
of 98%, which was followed with dyslipidemia 
in 46% subjects, diabetes in 30% subjects, 
smoking habit in 14% subjects and CAD in 8% 
Table 2. Clinical and laboratory characteristics of all 
subjects
Characteristics mean value
Age (years) 56.8 ± 9.8
Systolic blood pressure (mmHg) 130 (100-200)
Diastolic blood pressure (mmHg) 80 (60-110)
Fasting blood glucose (mg/dL) 95 (71-214)
Post-prandial blood glucose  
(mg/dL) 119 (72-238)
HbA1c 6 (4.4-9.7)
Total cholesterol (mg/dL) 166.5 (99-283)
HDL (mg/dL) 46.2 ± 11.7 
LDL (mg/dL) 101.5 (46-300)
Triglycerides (mg/dL) 110 (46-300)
Hemoglobin (g/dL) 13.6 ± 1.6
Hematocrit (%) 40.6 ± 4.5
Leukocytes (103/πL) 7.76 (3.76 – 14.6) 
Platelets (103/πL) 265 ± 53.4
Table 3. Prevalence of ASA resistance and socio-
demographic characteristics
Characteristics ASA resistance (n=7)
ASA response 
(n=43)
Sex
 - Male 6 (85.7%) 23 (53.5%)
 - Female 1 (14.3%) 20 (46.5%)
Age group
 - <40 years 1 (33.3%) 2 (66.7%)
 - 40-65 years 6 (15.4%) 33 (84.6%)
 - >65 years 0 (0%) 8 (100%)
Stroke onset
 - New stroke 1 (14.3%) 15 (34.9%)
 - Old stroke 6 (85.7%) 28 (65.1%)
Smoking
 - Active 4 (57.1%) 6 (14%)
 - No/stop smoking 3 (42.3%) 37 (86%)
Table 4. Prevalence of ASA resistance with concomitant 
disease
Characteristics ASA resistance (n=7)
ASA response 
(n=43)
Hypertension
 - Yes 7 (100%) 42 (97.7%)
 - No 0 (0%) 1 (2.3%)
Diabetes
 - Yes 1 (14.3%) 14 (32.6%)
 - No 6 (85.7%) 29 (67.4%)
Dyslipidemia
 - Yes 3 (42.9%) 20 (46.5%)
 - No 4 (57.1%) 23 (53.5%)
CAD 
 - Yes 1 (14.3%) 3 (7%)
 - No 6 (85.7%) 40 (93%)
Infection 
 - Yes 0 (0%) 4 (9.3%)
 - No 7 (100%) 39 (90.7%)
Inflammation
 - Yes 1 (14.3%) 4 (9.3%)
 - No 6 (85.7%) 39 (90.7%)
Table 5. Prevalence of ASA resistance with clinical and 
laboratory characteristics
Characteristics
ASA 
resistance 
(n=7)
ASA 
response 
(n=43)
Age (years) 51.3 ± 9.2 57.8 ± 9.7
Systolic blood 
pressure (mmHg) 130 (110-200) 135.6 ± 17.6
Diastolic blood 
pressure (mmHg) 78.6 ± 12.1 80 (60-110)
Fasting blood glucose 
(mg/dL) 97 (83-130) 95 (71-214)
Post-prandial blood 
glucose (mg/dL) 109 (72-238) 122 (75-234)
HbA1c 5.5 ± 0,6 6 (4.4-9.7)
Total cholesterol (mg/
dL) 140 (124-283) 173.9 ± 40.9
HDL (mg/dL) 46.7 ± 14.9 46.1 ± 11.3 
LDL (mg/dL) 77 (58-197) 109.2 ± 37.8
Triglycerides (mg/dL) 111.3 ± 54.2 110 (46-300)
Hemoglobin (g/dL) 13.5 ± 1.7 13.6 ± 1.6
Hematocrit (%) 40.0 ± 5.5 40.7 ± 4.4
Leukocytes (103/πL) 7.61 ± 1.75 8.10 ± 1.93 
Platelets (103/πL) 266 ± 73.9 265.3 ± 50.5
subjects. A study  conducted by Misbach J,3 
which evaluated 3723 patients with stroke in 44 
hospitals in 7 countries of ASEAN, reported that 
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55% patients with stroke are male, with mean 
age of 59.0 ± 13.8 years and 47% patients are at 
the age group of 45-64 years, with the highest 
risk factor of hypertension (67.5%), followed 
by TIA (26.1%), hypercholesterolemia (19%), 
smoking (18.8%), diabetes (17.6%) and coronary 
heart disease (3.5%). Characteristics of subject 
population in our study can represent the general 
characteristics of patients with ischemic stroke.
ASA has been used widely as the standard 
treatment for ischemic stroke, both for acute 
and chronic stroke. The treatment is effective 
for recurrent ischemic stroke prevention and 
has been proven to lower mortality rate in acute 
phase. The Chinese Acute Stroke Trial (CAST) 
and International Stroke Trial (IST) demonstrate 
that immediate ASA treatment in patients with 
ischemic stroke or suspected ischemic stroke 
can lower the risk of both fatal and non-fatal 
recurrent stroke significantly, reduce mortality 
rate in hospitals and increase functional recovery 
of patients with stroke.12
ATT Collaboration conducted a meta-
analysis involving 16 studies on secondary 
prevention of stroke, which reported that ASA 
treatment can significantly lower the incidence 
of recurrent ischemic stroke by 20% (p<0001).6 
Other than effective, the treatment is also 
cost friendly compared to other treatment of 
antiplatelet and it is covered by the national 
health insurance (JKN) for all Indonesian citizen. 
It becomes the first line treatment for all patients 
with ischemic stroke.
In reality, there are incidences of recurrent 
ischemic stroke in patients who have received 
regular ASA treatment. One of the causes is 
resistance to ASA treatment. ASA resistance 
is clinically defined as the inability of ASA 
treatment to prevent the development of recurrent 
ischemic stroke; while the laboratory definition 
of ASA resistance is the inability of ASA 
treatment to reduce the thromboxane A2 level 
or the inability to inhibit platelet aggregation.13,14 
There are various laboratory methods for 
evaluating ASA resistance. However, regardless 
of its assessment method, laboratory ASA 
resistance is associated with increased risk of 
recurrent ischemic stroke. A study conducted by 
Grotmeyer et al.10,15, evaluating 180 patients with 
ischemic stroke who received ASA treatment 
demonstrated that there were 33% of patietns 
with ASA resistance with 10 fold higher increase 
of recurrent ischemic stroke, myocardial infarct 
and death due to vascular events. The most recent 
study conducted by Zheng et al.16 showed that 
ASA resistance is associated significantly with 
the degree of severity of acute stroke in ASA 
resistance group with a median of National 
Institutes of Health Stroke Scale (NIHSS) score 
of 11 compared to the responsive ASA group, 
which had median NIHSS score of 4 (p<0.001). 
In our study we found that the prevalence 
of laboratory ASA resistance in patients with 
ischemic stroke at Cipto Mangunkusumo 
Hospital was 14%, which is a relatively high, 
in which 1 of 7 patients with ischemic stroke 
receiving routine ASA treatment actually did not 
respond to the treatment (ASA resistance). The 
prevalence rate is equivalent to results of study 
conducted by Kim et al.17, which evaluated 178 
patients with ischemic stroke and coronary artery 
disease (CAD) who received ASA treatment 
in Korea. The method of determining ASA 
resistance in our study is also similar to those in 
the study conducted by Kim et al,17 i.e. by using 
Verify now method with cut-off point ARU≥550 
Table 6. Prevalence of ASA resistance and characteristics 
of ASA treatment
Characteristics ASA resistance (n=7)
ASA response 
(n=43)
Enteric coated ASA 
 - Coating  2 (28.6%) 21 (48.8%)
 - No Coating 5 (71.4%) 22 (51.2%)
Duration of ASA 
treatment
 - Short duration 4 (57.1%) 19 (44.2%)
 - Long duration 3 (42.9%) 24 (55.8%)
Loading dose of 
ASA
 - Not given 6 (85.7%) 34 (79.1%)
 - Given 1 (14.3%) 9 (20.9%)
Interaction with 
NSAID 
 - Present 0 (0%) 0 (0%)
 - Absent 7 (100%) 43 (100%)
Interaction with PPI
 - Present 0 (0%) 7 (16.3%)
 - Absent 7 (100%) 36 (83.7%)
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is considered as ASA resistent.
The prevalence of ASA in our study is also 
almost similar to the results of study by Navarro 
et al18, that found ASA resistance of 10.4% in 
77 patients with ischemic stroke in Philippine 
using Ultegra (which has similar principles on 
mechanism of action to the verify now method) 
with an equal cut-off point, i.e. ARU≥550 is 
defined as ASA resistant. The similarity of results 
on the prevalence of ASA resistance in those three 
studies may be caused by the similarity in method 
of assay, similar cut-off point for ASA resistance 
of ARU≥550, similar sociodemographic and 
clinical characteristics as well as concomitant risk 
factors in patients with ischemic stroke who had 
become the subjects of studies and may be also 
because of similar genetic factors.
Many factors have been assumed to be the 
cause of ASA resistance, including the factor 
of using enteric coating ASA, interaction with 
other drugs, duration of treatment, the presence 
of concomitant disease and smoking habit.
In our study, there was a tendency of greater 
ASA resistance in the group of male subjects 
compared to the female subjects, in the age group 
of <40 years compared to those of >65 years 
and in the group of active smoker compared 
to those who were not smokers or had stopped 
smoking. However, further statistical analysis is 
not possible to be done considering the limited 
number of samples. The tendency found in our 
study is consistent with the results of previous 
studies on the prevalence of ASA resistance. A 
study conducted by Zheng et al.16, evaluating the 
prevalence of ASA resistance in 90 patients with 
acute ischemic stroke at the Royal Melbourne 
Hospital, Australia found a significant correlation 
between the prevalence of ASA resistance and 
patients’ smoking habit (OR 3.08; 95% CI, 
1.17-8.13; p=0.02). It is assumed that smoking 
can increase the production of isoprostane 
(a prostaglandin-F2-like substance) that can 
produce thromboxane from the alternative non-
COX pathway, which is not inhibited by ASA.19
Regarding the correlation between ASA 
resistance and demographic, clinical, laboratory 
and treatment characteristics, various studies, 
including the studies conducted by Ozben et 
al.11 and Kim et al.17 did not find a significant 
difference of concomitant disease such as 
hypertension, diabetes, dyslipidemia and other 
laboratory parameters with characteristics of 
treatment between the group of ASA resistant 
and ASA responsive. In our study, although 
there is a tendency that all patients who have 
ASA resistance are also have hypertension, but 
an evaluation to study statistical correlation was 
not possible due to a small number of subjects.
CONCLUSION
Our study found a relatively high prevalence 
of laboratory ASA resistance in patients with 
ischemic stroke at Cipto Mangunkusumo Hospital, 
i.e. as many as 14%, which means that 1 out of 
7 patients with ischemic stroke who receive ASA 
treatment still have the risk for recurrent stroke 
because of resistance to the treatment.
There is a tendency that the prevalence of 
laboratory ASA resistance is higher in male 
patients, active smoker, younger patients and 
those with hypertension; however, to confirm 
the statistical significancy, further studies must 
be carried out with a larger sample size.
REFERENCES
1. Hardie K, Hankey GJ, Jamrozik K, Broadhurst RJ, 
Anderson C. Ten-year risk of first recurrent stroke and 
disability after first-ever stroke in the perth community 
stroke study. Am Heart J. 2004;35:731-5.
2. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart 
disease and stroke statistics 2012 update: a report 
from the American Heart Assosiation. Circulation. 
2012;25:e2-e220.
3. Misbach J, Ali W. Stroke in Indonesia: a first large 
prospective hospital-based study of acute stroke in 28 
hospitals in Indonesia. J Clin Neurosci. 2001;8:245-9.
4. Antiplatelet Trialists Collaboration. Collaborative 
overview of  randomised trials of antiplatelet therapy: 
Prevention of death, myocardial infarction, and stroke 
by prolonged antiplatelet therapy in various categories 
of patients. BMJ. 1994:81-106.
5. Antiplatelet Trialists Collaboration. Collaborative 
meta-analysis of randomised trials of antiplatelet 
therapy for prevention of death, myocardial infarction, 
and stroke in high risk patients. BMJ. 2002:71-86.
6. Dai Y, Ge J. Clinical use of aspirin in treatment and 
prevention of cardiovascular disease. Thrombosis. 
2012;2012:1-7.
7. Knoepp SM, Laposatta M. Moving forward with 
multiple definitions, different assays, and a clinical 
imperative. Am J Clin Pathol. 2005;123:125-32.
M. Kurniawan                                                                                                         Acta Med Indones-Indones J Intern Med
94
8. Meadows TA, Bhatt DL. Clinical aspects of platelet 
inhibitors and thrombus formation. Am Heart J. 
2007;100:1261-75.
9. Topcuoglu MA, Arsava EM, Hakan AY. Antiplatelet 
resistance in stroke. Expert Rev Neurother. 
2011;11:251-63.
10. Manson PJ, Jacobs AK, Freedman JE. Aspirin 
resistance and atherothrombotic disease. J Am Coll 
Cardiol. 2005;46:986-92.
11. Ozben S, Ozben B, Tanrikulu AM, Ozer F, Ozben 
T. Aspirin resistance in patients with acute ischemic 
stroke. J Neurol. 2011;258:1979-86.
12. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 
2006;367:606-17.
13. Michos ED, Ardehali R, Blumenthal RS, Lance RA, 
Ardehali H. Aspirin and clopidogrel resistance. Mayo 
Clin Proc. 2006;14:518-26.
14. Patrono C. Aspirin resistance: definition, mechanism, 
and clinical read-outs. J Thromb Haemost. 2003;1:1710-
3.
15. Zimmermann N, Hohlfeld T. Clinical implications of 
aspirin resistance. Thromb Hemos. 2008;100:379-90.
16. Zheng AS, Churilov L, Colley RE, Gog C, Davis 
SM, Yan B. Association of aspirin resistance with 
increased stroke severity and infarct size. J Neurol. 
2013;70(2):208-12.
17. Kim H, Lee HK, Han K, Jeon HK. Prevalence and 
risk factors for aspirin and clopidogrel resistance 
in patients with coronary artery disease or ischemic 
cerebrovascular disease. Ann Clin Lab Sci. 
2009;39:289-93.
18. Navarro JC, Lao AY, Yumul MP, Araullo MLC, Lokin 
JK, II ACB. Aspirin resistance among patients with 
recurrent non-cardioembolic stroke detected by rapid 
platelet function analyzer. Neurol Asia. 2007;12:89-95.
19. Gotto AM, Pownall HJ. Atherosclerosis. In: Weinberg 
R, ed. Manual of lipid disorders. Third ed. Philadelphia: 
Lippincott Williams & Wilkins; 2003. p. 68-122.
20. Chen WH, Cheng X, Lee PY, et al. Aspirin resistance 
and adverse clinical events in patients with coronary 
artery Disease. Am J Med. 2007;120:631-35.
